We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Fluxergy Collaborates with Mass General Brigham to Evaluate One-Hour COVID-19 Diagnostic Test

By HospiMedica International staff writers
Posted on 03 Jul 2020
Fluxergy (Irvine, CA, USA) will work with Mass General Brigham (MGB Boston, MA, USA) to further evaluate the company’s innovative Research Use Only (RUO) COVID-19 testing platform, designed to deliver accurate PCR test results in under one hour.

Fluxergy has filed a request for an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). If granted, the EUA would permit medical sites with CLIA-certified high complexity laboratories, such as MGB, to use the Fluxergy system as a COVID-19 diagnostic tool in accordance with the FDA's authorization. Subject to confirming the performance of the Fluxergy system, and the potential receipt by Fluxergy of the EUA, MGB may utilize the new platform within its healthcare system. MGB also has plans to publish its findings for review by other medical institutions.

Image: The Fluxergy diagnostic testing system (Photo courtesy of Fluxergy)
Image: The Fluxergy diagnostic testing system (Photo courtesy of Fluxergy)

Fluxergy is also working to develop additional validation data that may support a possible future EUA request to use its COVID-19 testing system at the point-of-care, such as at physician offices, urgent care centers, and outreach clinics. Fluxergy has also begun initial work developing a first-of-its-kind multimodal test that may be able to perform a combined PCR and immunoassay (antibody) COVID-19 analysis using a single Fluxergy test card.

"MGB is committed to working collaboratively with innovators in the medical field like Fluxergy to help assess new technologies that may enable our hospitals and other medical institutions to more quickly and accurately identify patients with COVID-19, and keep medical staff safely on the job," said Lauren Ritterhouse, MD, PhD, Associate Director for the Center for Integrated Diagnostics in the Department of Pathology at Massachusetts General Hospital, and Assistant Professor at Harvard Medical School.

"Fluxergy is proud to work with Mass General Brigham, one of the nation's most respected healthcare systems, to assist in evaluating the efficacy of the Fluxergy COVID-19 PCR test," said Dr. Ali Tinazli, Fluxergy's Chief Commercialization Officer.

Related Links:
Fluxergy
Mass General Brigham



Gold Member
12-Channel ECG
CM1200B
New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
X-ray Diagnostic System
FDX Visionary-A
New
Hospital Data Analytics Software
OR Companion

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles